DRUG BILIGAND CONJUGATE AND USE THEREOF Russian patent published in 2024 - IPC A61K47/55 A61K31/4745 A61K47/64 A61K47/65 A61P35/00 A61P37/02 

FIELD: chemistry.

SUBSTANCE: group of inventions relates to biomedical chemistry. Disclosed are conjugated compounds or pharmaceutically acceptable salts thereof, in which the payload is conjugated with at least one of the targeting molecules. Targeting molecules are a moiety which is a synergistic molecule which binds to a molecule selected from a group consisting of FOLR1, TRPV6, SSTR2 and GNRHR, and a fragment representing a ligand to a prostate-specific membrane antigen. In another embodiment, the conjugate contains a fragment which is a ligand of formula (I), or P10, and the synergistic molecule binds to the FOLR1 molecule. Also disclosed is a pharmaceutical composition, a method for delivering a payload to a subject, a method of treating a disease, wherein the methods involve administering to a subject a therapeutically effective amount of a conjugated compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

EFFECT: inventions enable to enhance the affinity and specificity of targeting drug compounds, thereby delivering the highly effective chemotherapeutic agents to the patient, extending the therapeutic window of such agents, and avoiding side effects.

37 cl, 8 dwg, 31 tbl, 5 ex